Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Cancer Vaccines Equipment Supplied In Europe
21 equipment items found
Manufactured by:Scancell based inOxford, UNITED KINGDOM
ImmunoBody vaccines are designed to generate potent T cell responses capable of a broad anti-tumour effect. They are DNA vaccines that encode a protein in the form of an antibody, but the parts of the antibody that would normally bind to the target protein are replaced with epitopes from a cancer ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
Modi-1 is the first vaccine based on Scancell’s Moditope® platform. The vaccine is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. The first is the cytoskeletal protein, vimentin, which is preferentially digested during autophagy. All mesenchymal tumours such as ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
Effective antigen delivery and a strong and durable response is the basis for successful cancer vaccines. The SVLP approach, with its modular and flexible design, the inherent adjuvant properties and other immune system activators, lends itself to the development of particle-based vaccines against cancer: SVLPs displaying ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
Scancell’s lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. SCIB1 incorporates specific epitopes from the proteins gp100 and TRP-2, which were identified from the cloning of T cells from patients who achieved spontaneous recovery from melanoma skin cancers. ...
Manufactured by:Ardigen based inKraków, POLAND
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to generate and prioritize antigen targets for cancer vaccines and T-cell ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
The Modi-2 vaccine exploits a second post-translational modification, stimulating the production of CD4 T cells using tumour-associated peptide epitopes in which the lysine residues are converted to homocitrulline. This change occurs via a process known as carbamylation, leading to a change in molecular charge which, in turn, alters antigenic properties and can result in the generation of unique ...
Manufactured by:ViciniVax BV based inGroningen, NETHERLANDS
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first clinical trial, which has been started in ...
Manufactured by:Enterome based inParis, FRANCE
OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, respectively. ...
Manufactured by:Enterome based inParis, FRANCE
EO4010 is an innovative, off-the-shelf therapeutic cancer vaccine currently in discovery. EO4010 peptides combination will include two OncoMimics (bacterial peptides) already used in EO2401 and one or two additional peptides in an indication with high unmet medical need and market potential. ...
Manufactured by:Enterome based inParis, FRANCE
EO2463 is an innovative, off-the-shelf therapeutic cancer vaccine discovered by Enterome. EO2463 combines four OncoMimics peptides (bacterial peptides) of B lymphocyte-specific lineage markers. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in indolent non-Hodgkin ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors was observed after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene AG, it was ...
Manufactured by:eTheRNA based inNiel, BELGIUM
Therapeutic area: cancer vaccines; Systemic, intravenous (IV) ...
Manufactured by:leon-nanodrugs GmbH based inMunich, GERMANY
The closed disposable system enables aseptic processing, allowing for rapid production of individual batches without the risk of cross-contamination, and eliminates the need for cleaning and sterilization steps in between batches. NANOme is highly adaptable for clinical use in personalized medicines such as therapeutic cancer vaccines and as an adjunct to ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also for boys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a ...
by:Thermo Fisher Scientific, LIMS & Laboratory Software based inPhiladelphia, PENNSYLVANIA (USA)
Cell Therapy Systems—a proven choice for clinical cell therapy manufacturing. As you move from basic cell therapy research to the clinic, high-quality GMP-grade cell therapy ancillary materials and proper documentation are essential to getting it right the first time. Cell Therapy Systems (CTS) products provide a proven choice for clinical stem cell therapy and immunotherapy research and ...
Manufactured by:ORYX GmbH & Co. KG based inBaldham, GERMANY
The human cyclin-dependent kinase inhibitor p16INK4a is a tumor antigen expressed in various cancers, including lung and breast cancer. In normal cells, p16INK4a is rarely expressed and leads to immediate senescence. In all cancers associated with high risk human papilloma virus (HR-HPV), p16INK4a is constantly expressed as an early consequence ...
by:NEC OncoImmunity AS based inOslo, NORWAY
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in immuno-oncology and the rapid advances in next generation sequencing (NGS), opens up exciting new opportunities to harness neoantigens for their therapeutic and ...
Manufactured by:Prima Lab SA based inBalerna, SWITZERLAND
COVID-19 Neutralising IgG Serological Test is a rapid device which verifies the presence of COVID-19 neutralising IgG antibodies in human blood samples produced after the end of the vaccination cycle. ...